trial

Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

NCTId NCT00439634
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 873 (actual)
Sponsored by Sanofi
Primary completion 2009-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
873 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2007-02
Primary completion
2009-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
AVE1625

Sponsors

SanofiLead Sponsor

Investigators

1
ICD CSDStudy Director

Sites

2 total
Bridgewater, United StatesLaval, Canada

Linked catalysts

1
Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in S — primary completion2009-09

Facts & assertions

4 sourced
Enrollment
873
Phase
PHASE2
Primary Completion Date
2009-09
Status
TERMINATED
relationships
The graph out of here
drug
AVE1625
drug
lead_sponsor
Sanofi
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
ICD CSD
person